Home › Trial NCT04203485
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
- Trial IDNCT04203485
- StatusUnknown
- PhasePhase 3
- Study typeInterventional
- SponsorJiangsu HengRui Medicine Co., Ltd.
- Enrollment762
- Start date2020-06-15
- ConditionsPD-L1 Positive Non-small Cell Lung Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.